Bone Marrow Aspirate Concentrate Combined With an Appropriate Carrier Effectively Promotes Bone-Tendon Interface...

Area of Science:

• Orthopedics
• Regenerative Medicine
• Biomaterials Science

Background:

• The effectiveness of bone marrow aspirate concentrate (BMAC) for bone-tendon interface (BTI) healing without carriers is debated.
• Investigating carriers for BMAC is crucial for optimizing tendon regeneration therapies.

Purpose of the Study:

• To evaluate the impact of different carriers on BMAC efficacy for tendon regeneration.
• To assess BMAC with polydeoxyribonucleotide (PDRN) and atelocollagen (ATC) in a rabbit model of chronic rotator cuff tear.

Main Methods:

• In vitro assessment of growth factor levels and BMAC differentiation potential with PDRN and ATC.
• In vivo study involving 64 rabbits divided into four groups: control, BMAC, BMAC-PDRN, and BMAC-ATC.
• Histological, genetic, and biomechanical analyses at 4 and 12 weeks post-repair.

Main Results:

• BMAC with ATC demonstrated superior in vitro multilineage differentiation compared to BMAC alone or with PDRN.
• The BMAC-ATC group exhibited significantly higher expression of aggrecan, BMP-2, and COL1A1 in vivo.
• Enhanced collagen fiber continuity, density, and mature BTI were observed in the BMAC-ATC group, alongside superior load-to-failure strength.

Conclusions:

• BMAC requires appropriate carriers, like ATC, to effectively enhance BTI healing.
• The combination of BMAC and ATC shows significant potential as a biological agent for promoting rotator cuff tendon healing.